Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New infusion drug hopes to slow Alzheimer's in early stages

NCT ID NCT07094516

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called VHB937 in people with early Alzheimer's disease. About 400 participants will receive either the drug or a placebo by infusion over 72 weeks. The goal is to see if the drug can slow down memory and thinking problems. Researchers will also check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VHB937 (a biologic drug given by infusion)
What this could lead to
If it works, this could point toward a treatment that slows cognitive decline in early Alzheimer's disease.
What could go wrong
This is a Phase 2 trial, so it is still early. The drug may not show benefit or could have side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 407 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria * Male or female participants 50 to 85 years of age * Diagnosis of Mild Cognitive Impairment (MCI) due to AD or mild AD * Clinical Dementia Rating (CDR) Global score of 0.5 or 1.0 * Confirmation of AD based on cerebral spinal fluid (CSF) biomarkers or amyloid PET imaging * Reliable study partner who can accompany the participant at study visits * If on symptomatic AD treatment (AChEIs/memantine), on a stable dose prior to starting study treatment Key Exclusion Criteria * Dementia due to a condition other than AD, including but not limited to, frontal temporal dementia, Parkinson's disease, dementia with Lewy bodies, Huntington disease, vascular dementia. * History or current diagnosis of cardiac conditions or ECG abnormalities indicating significant risk of safety for participants in the study * Transient ischemic attacks (TIA) or stroke occurring within 12 months * Clinical evidence of liver or renal disease/injury * Current major depressive episode that is not adequately controlled, history of schizophrenia, other chronic psychosis * Significant neurological disease other than dementia (e.g. serious brain infection, traumatic brain injury, multiple concussions, epilepsy or recurrent seizures * Presence of suicidal ideation within 6 months or suicidal behavior within 2 years before Screening * Presence of cancer, HIV, Hep B, Hep C, uncontrolled thyroid disease, uncontrolled diabetes * Taking any prohibited medications Other protocol-defined inclusion/exclusion criteria may apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer's disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    74 sites in 15 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Abington Neurological Associates Ltd

    RECRUITING

    Willow Grove, Pennsylvania, 19090, United States

  • ActivMed Practices and Research

    RECRUITING

    Methuen, Massachusetts, 01844, United States

  • Alzheimers Research Treatment Ctr

    RECRUITING

    Wellington, Florida, 33414, United States

  • Alzheimers Research Treatment Ctr

    RECRUITING

    Wellington, Florida, 33414, United States

  • Banner Alzheimers Institute

    RECRUITING

    Phoenix, Arizona, 85006, United States

  • Charter Research The Villages

    RECRUITING

    The Villages, Florida, 32162, United States

  • Citizens Memorial Hospital Neurology CLinic

    RECRUITING

    Bolivar, Missouri, 65613, United States

  • Conquest Research

    RECRUITING

    Winter Park, Florida, 32789, United States

  • Hawaii Pacific Neuroscience LLC

    RECRUITING

    Honolulu, Hawaii, 96817, United States

  • Irvine Center for Clinical Research

    RECRUITING

    Irvine, California, 92618, United States

  • Jem Research Institute

    RECRUITING

    Atlantis, Florida, 33462-6608, United States

  • K2 Medical Research LLC

    RECRUITING

    Maitland, Florida, 32751, United States

  • K2 Medical Research LLC

    RECRUITING

    Maitland, Florida, 32751, United States

  • Lou Ruvo Center for Brain Health

    RECRUITING

    Las Vegas, Nevada, 89106, United States

  • Neural Net Research

    RECRUITING

    Portland, Oregon, 97225, United States

  • Novartis Investigative Site

    RECRUITING

    Camperdown, New South Wales, 2050, Australia

  • Novartis Investigative Site

    RECRUITING

    Kogarah, New South Wales, 2217, Australia

  • Novartis Investigative Site

    RECRUITING

    Box Hill, Victoria, 3128, Australia

  • Novartis Investigative Site

    RECRUITING

    Heidelberg, Victoria, 3084, Australia

  • Novartis Investigative Site

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • Novartis Investigative Site

    RECRUITING

    London, Ontario, N6G 3H7, Canada

  • Novartis Investigative Site

    RECRUITING

    North York, Ontario, M6A 2C8, Canada

  • Novartis Investigative Site

    RECRUITING

    Ottawa, Ontario, K1N 5C8, Canada

  • Novartis Investigative Site

    RECRUITING

    Toronto, Ontario, M3B 2S7, Canada

  • Novartis Investigative Site

    RECRUITING

    Toronto, Ontario, M5T 2S8, Canada

  • Novartis Investigative Site

    RECRUITING

    Hangzhou, Zhejiang, 310002, China

  • Novartis Investigative Site

    RECRUITING

    Shanghai, 200040, China

  • Novartis Investigative Site

    RECRUITING

    Brno, 602 00, Czechia

  • Novartis Investigative Site

    RECRUITING

    Prague, 160 00, Czechia

  • Novartis Investigative Site

    RECRUITING

    Toulouse, Haute Garonne, 31059, France

  • Novartis Investigative Site

    RECRUITING

    Paris, 75013, France

  • Novartis Investigative Site

    RECRUITING

    Berlin, State of Berlin, 12200, Germany

  • Novartis Investigative Site

    RECRUITING

    Berlin, 13353, Germany

  • Novartis Investigative Site

    RECRUITING

    München, 80377, Germany

  • Novartis Investigative Site

    RECRUITING

    Cefalù, PA, 90015, Italy

  • Novartis Investigative Site

    RECRUITING

    Perugia, PG, 06129, Italy

  • Novartis Investigative Site

    RECRUITING

    Ōbu, Aichi-ken, 4748511, Japan

  • Novartis Investigative Site

    RECRUITING

    Fujioka, Gunma, 375-0017, Japan

  • Novartis Investigative Site

    RECRUITING

    Itabashi Ku, Tokyo, 1730015, Japan

  • Novartis Investigative Site

    RECRUITING

    Kodaira, Tokyo, 187-8551, Japan

  • Novartis Investigative Site

    RECRUITING

    Shinjuku Ku, Tokyo, 160-0023, Japan

  • Novartis Investigative Site

    RECRUITING

    Amsterdam, 1081 GN, Netherlands

  • Novartis Investigative Site

    RECRUITING

    Bialystok, 15-756, Poland

  • Novartis Investigative Site

    RECRUITING

    Oświęcim, 32-600, Poland

  • Novartis Investigative Site

    RECRUITING

    Wroclaw, 53659, Poland

  • Novartis Investigative Site

    RECRUITING

    Seoul, Korea, 05505, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Seoul, 03080, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Seoul, 05030, South Korea

  • Novartis Investigative Site

    RECRUITING

    Incheon, 21565, South Korea

  • Novartis Investigative Site

    RECRUITING

    Incheon, 22332, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 04763, South Korea

  • Novartis Investigative Site

    RECRUITING

    Pamplona, Navarre, 31008, Spain

  • Novartis Investigative Site

    RECRUITING

    Valencia, Valencia, 46017, Spain

  • Novartis Investigative Site

    RECRUITING

    Valencia, 46026, Spain

  • Novartis Investigative Site

    RECRUITING

    Mölndal, 431 80, Sweden

  • Novartis Investigative Site

    RECRUITING

    Stockholm, 141 86, Sweden

  • Novartis Investigative Site

    RECRUITING

    Edinburgh, Lothian, EH12 5PJ, United Kingdom

  • Novartis Investigative Site

    RECRUITING

    Oxford, Oxfordshire, OX3 7JX, United Kingdom

  • Novartis Investigative Site

    RECRUITING

    Aberdeen, AB25 2ZH, United Kingdom

  • Novartis Investigative Site

    RECRUITING

    London, SE5 8AF, United Kingdom

  • Novartis Investigative Site

    RECRUITING

    London, W1G 9JF, United Kingdom

  • Novartis Investigative Site

    RECRUITING

    London, WC1N 3BG, United Kingdom

  • Novartis Investigative Site

    RECRUITING

    Newcastle upon Tyne, NE4 6BE, United Kingdom

  • Novartis Investigative Site

    RECRUITING

    Salford, M6 8HD, United Kingdom

  • Novartis Investigative Site

    RECRUITING

    Southampton, SO16 6YD, United Kingdom

  • Renstar Medical Research

    RECRUITING

    Ocala, Florida, 34471, United States

  • The Ohio State University

    RECRUITING

    Columbus, Ohio, 43210, United States

  • UNC Hosp Invest Drug Serv Pharm

    RECRUITING

    Chapel Hill, North Carolina, 27514, United States

  • University of California San Diego

    RECRUITING

    La Jolla, California, 92037, United States

  • University of California at Los Angeles

    RECRUITING

    Los Angeles, California, 90095, United States

  • University of Kansas Hospital

    RECRUITING

    Fairway, Kansas, 66205, United States

  • University of Texas Health Science Center at San Antonio

    RECRUITING

    San Antonio, Texas, 78229-3900, United States

  • University of Washington Medical Center

    RECRUITING

    Seattle, Washington, 98195, United States

  • Visionary Investigators Network

    RECRUITING

    Aventura, Florida, 33180, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.